The news: President Trump is threatening 200% tariffs on pharma products, but the 1+ year lag in enforcement gives drugmakers time to increase US manufacturing. 

Zooming in: Trump promised 200% tariffs during a cabinet meeting this week, stating there would be a 12- to 18-month delay for companies to “get their act together.” 

Trump’s original 90-day pause of 25% tariffs on pharmaceuticals was set to expire July 9, but extended to August 1.

• Details about the 200% tariffs will be released at the end of the month after the administration’s ongoing Section 232 national security investigation concludes, Commerce Secretary Howard Lutnick said.
• US investors mostly shrugged off the news with pharma stock prices largely unchanged.

Zooming out: A handful of pharma companies made US manufacturing commitments in the spring under pressure from the Trump administration. An executive order in May also instructed health regulators to cut bureaucratic red tape to make pharma manufacturing easier in the US. 

• In February, Eli Lilly added $27 billion to its already promised $23 billion in new manufacturing.
• In March, Johnson & Johnson pledged $55 billion over four years in US R&D, tech and manufacturing.
• In April, Novartis promised to spend $23 billion, while Roche pledged $50 billion over five years on new facilities and expansions. Roche said its commitment will flip it to a majority exporter of US medicines.

Why it matters: Pharma companies have been sweating out the proposed tariff details for months. Most drug ingredients, called active pharmaceutical ingredients (APIs), are made outside the US.

• 43% of brand-name drug APIs come from the EU, and only 15% from the US, per a US Pharmacopeia analysis of 2024 imports.  
• 35% of generic drug APIs are made in India, 18% in the EU and 8% in China. The US accounts for 12% of generic APIs, per the USP analysis.

Our take: While 200% is an exorbitant tariff rate, the year-long reprieve is a win for drugmakers. It gives them time to move product and double down on US manufacturing commitments, and also opens a big window for change with the capricious Trump administration.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.